Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome

Luciano Cardinale, Francesco Asteggiano, Federica Moretti, Federico Torre, Stefano Ulisciani, Carmen Fava, Giovanna Rege-Cambrin

Abstract

In acute promyelocytic leukemia, differentiation therapy based on all-trans-retinoic acid can be complicated by the development of a differentiation syndrome (DS). DS is a life-threatening complication, characterized by respiratory distress, unexplained fever, weight gain, interstitial lung infiltrates, pleural or pericardial effusions, hypotension and acute renal failure. The diagnosis of DS is made on clinical grounds and has proven to be difficult, because none of the symptoms is pathognomonic for the syndrome without any definitive diagnostic criteria. As DS can have subtle signs and symptoms at presentation but progress rapidly, end-stage DS clinical picture resembles the acute respiratory distress syndrome with extremely poor prognosis; so it is of absolute importance to be conscious of these complications and initiate therapy as soon as it was suspected. The radiologic appearance resembles the typical features of cardiogenic pulmonary edema. Diagnosis of DS remains a great skill for radiologists and haematologist but it is of utmost importance the cooperation in suspect DS, detect the early signs of DS, examine the patients’ behaviour and rapidly detect the complications.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Differentiation syndrome; All-trans-retinoic acid syndrome; Chest X-ray and computed tomography; Lungleukemic infiltrates; Acute promyelocytic leukaemia; Promyelocytic leukaemia/retinoic acid receptor-α

Core tip: Aim of this review is to illustrate the spectrum of chest imaging findings which lead to suspect a diagnosis of differentiation syndrome, which arise in patients suffering of Acute Promyelocytic Leukaemia after treatment with all-trans-retinoic acid or other differentiating drugs, in order to facilitate the differential diagnosis with other life-threatening pulmonary complications occurring in this subset of highly immunocompromised patients.

Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, Fava C, Rege-Cambrin G. Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. World J Radiol 2014; 6(8): 583-588 Available from: URL: http://www.wjgnet.com/1949-8470/full/v6/i8/583.htm DOI: http://dx.doi.org/10.4329/wjr.v6.i8.583

LEARNING OBJECTIVES

The treatment of acute promyelocytic leukaemia with agents capable of inducing the differentiation of leu-
kemic cells can be complicated by a peculiar syndrome, named differentiation syndrome (DS); this was previously classified as retinoic acid syndrome, as all-trans-retinoic acid (ATRA) was the first agent to be involved in this complication. DS is a syndrome of cardiac and respiratory distress which represents a life-threatening complication, and is associated with severe morbidity and mortality; so early diagnosis and immediate therapeutic intervention are essential in reducing the risk of death[9].

In this work we illustrate the imaging findings on chest X-ray, and in standard or high-resolution computed tomography (CT) useful to suggest this uncommon diagnosis. The aim of this work is to underline the importance of an early diagnosis of DS, to show how radiologists can confirm the diagnosis of DS, to stimulate the cooperation and communication between radiologists and clinicians.

**BACKGROUND**

Acute promyelocytic leukemia (APL), identified as acute myeloid leukaemia (AML) M3 by the French-American-English classification, is an acute myeloid disorder due to a maturative block of myeloid precursor at the promyelocytic stage, leading to peculiar clinical manifestations, and characterized by a reciprocal balanced translocation between chromosomes 15 and 17 \((15, 17)\)[2]. APL represents about 10% of all AML in United States and Europe and is more frequent in adults; median age at diagnosis is 40[4].

The finding of a translocation \((15, 17)\), with a consequent transcriptional fusion between promyelocytic leukaemia (PML) gene and retinoic acid receptor-\(\alpha\) (RAR\(\alpha\)) gene, responsible of the maturative and differentiative stop, offered the basis to develop a specific target therapy with retinoic acid. PML-RAR\(\alpha\) rearrangement is detectable in approximately 95% of APL cases[12,14].

APL is usually a primitive disorder, but there are also cases of APL arising following a previous exposure to chemotherapy or radiotherapy[15].

On the clinical side APL represents a hematologic emergency because of its typical presentation with pancytopenia and a life-threatening disseminated intravascular coagulation, that enforces a quick start of treatment, even before a cytogenetic and molecular diagnosis. Diagnosis of APL is usually based on peripheral blood and bone marrow morphology, supported by typical laboratory and clinical picture. Confirmation then comes from the molecular finding of PML-RAR\(\alpha\) rearrangement. Treatment of APL is based on the association of ATRA with conventional chemotherapy (usually anthracyclines), or with arsenic trioxide (ATO). Since the introduction of ATRA in the treatment, the complete remission rate raised up to 90% and the 5-year disease free survival to 74%[5,9].

Induction treatment with ATRA and ATO, either as a single agent or in combination with cytotoxic drugs, can induce the DS[9] in 2% to 31% of APL patients[16,17], while the association with chemotherapy compared with ATRA as single-agent lead to a reduction risk of DS (9% vs 18%-25%)[12,13]. Mortality due to DS has declined from 30% to 2%-10% because of the early recognition and clinical intervention[10]. Notably, DS is rarely seen during consolidation and maintenance phases[12,14,15].

The pathophysiology of DS is not completely understood. Both ATRA and ATO exert their action by degradation of the PML-RAR\(\alpha\) fusion product. As a consequence, malignant leukemic cells undergo differentiation and final maturation[16,17].

Exposition to ATRA and ATO cause continued generation of inflammatory cytokines and adhesion molecules, with the consequent extravasation into the tissues from the blood. Increased in cytokine and adhesion molecules level also occurs in liver, heart and spleen[10,18].

DS is typically diagnosed during the first induction treatment, more often 10 to 12 d after therapy start, with a range of 2 to 46 d[10,11,18-20]. Main symptoms at presentation are fever, respiratory failure and fluid retention with weight increase, occurring in around 80% of the cases[10,18]. Additional common findings are lung infiltrates (50%), pericardial and pleural effusions (50%) and acute renal failure (10% of the cases)[18]. DS has to be distinguished from other clinical conditions which may occur in the setting of acute leukaemia, including pulmonary infection, leukostasis, and heart failure. Diagnosis of DS is made when three or more of the symptoms and signs listed in Table 1 are present. Clinical management and outcome are greatly influenced by early pharmacological treatment. Dexamethasone must be used at a dosage of 10 mg twice daily iv as soon as DS is suspected. Steroid treatment should continue until DS resolves, and then the dosage can be gradually tapered in the following weeks[21,22]. Hemodynamic and ventilatory support is also indicated in severe cases, which may require admission at the intensive care unit. In Table 2, modified from[23], the measures to be taken at suspicion of DS are reported. Discontinuation of treatment with ATRA (or ATO) is mandatory in severe DS cases[9]. Corticosteroid are commonly used as DS prophylaxis, although there is no evidence that such treatment may ameliorate the morbidity and mortality of DS. However, in patients with leukocytosis at diagnosis (white blood cells > 5 × 10^9/L), preemptive steroids administration has been shown useful in reducing incidence and severity of DS. No definite risk factors for developing DS were found, but a close monitoring of patients presenting with hyperleukocytosis

| Table 1 Signs and symptoms |
|-----------------------------|
| Differentiation syndrome: Sign and symptoms |
| Elevated white blood cell count | Weight gain > 5 kg |
| Dyspnea | Bone pain |
| Respiratory distress | Headache |
| Fever | Hypotension |
| Pulmonary edema | Congestive heart failure |
| Pulmonary infiltrates | Acute renal failure |
| Pleural and pericardial effusion | Hepatotoxicity |

**Table 1** Signs and symptoms
Cardinale L et al. Imaging of all-trans-retinoic acid syndrome

Figure 1 Correlation between white blood cell count and chest X-ray. Note that the worsening of chest X-ray is directly linked with the fall of white blood cell due to the massive differentiation during the onset of differentiation syndrome. References: Institute of Radiology, Department of Clinical and Biological Sciences of University of Turin, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Torino, Italy. WBC: White blood cells.

Table 2 Measures at suspicion of differentiation syndrome

| Measures at suspicion of DS | WBC (× 1000/(µL) (4.5-11.0) |
|----------------------------|-----------------------------|
| Chest X-ray, renal function (creatinine and urea), hepatic function (amino transferases and bilirubin), blood cell counts, coagulation test, oxygen saturation | 24-Jul 26-Jul 28-Jul 29-Jul 30-Jul 1-Aug 3-Aug 6-Aug 14-Aug |
| Weight monitoring | 20 |
| Ventilatory support/O2 supplementation | 30 |
| Blood pressure maintenance measures | 40 |
| Fluid restriction (renal failure) | 50 |
| Steroid administration at first suspicion: dexamethasone 10 mg twice daily until clinical resolution, then tapered dose for a few days | 60 |
| Suspend ATRA or ATO in severe cases, which can be restarted after clinical improvement. If DS recurs after restart, ATRA must be definitively discontinued during induction | 70 |

Some patients have DS that is refractory to corticosteroids. There are yet no widely accepted alternatives to it. It seems reasonable to employ, in the future, agents that block migration, adhesion or transmigration of APL cells. References: Institute of Radiology, Department of Clinical and Biological Sciences of University of Turin, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Torino, Italy. DS: Differentiation syndrome; ATRA: All-trans-retinoic acid; ATO: Arsenic-trioxide.

is recommended\(^{[22,23]}\).

A better knowledge and early identification of DS, with rapid initiation of treatment, allowed to obtain a decrease in mortality associated with APL in the recent years.

**IMAGING FINDINGS**

As stated before, there are no clinical signs or laboratory tests to diagnose DS, nor is there a radiological finding pathognomonic for DS.

Radiologic features may be explained by the proposed hypotheses of pathophysiology of the DS\(^{[6,9]}\). Most of the patients with DS showed cardiomegaly, widening of the vascular pedicle width, increased pulmonary blood volume, peribronchial cuff, ground-glass opacity, septal lines, and pleural effusion: these findings are similar to those of congestive heart failure with pulmonary edema, but they could also probably be produced by leukemic lung infiltration and endothelial leakage\(^{[24]}\).

If the disease progresses, acute respiratory distress syndrome develops. Diffuse alveolar damage and massive intra-alveolar hemorrhage were found in a necropsy patient study by Frankel et al\(^{[25]}\). Endothelial cell damage, including intra-alveolar oedema, intra-alveolar hemorrhage, and fibrinous exudate, were found by Tallman et al\(^{[26]}\) and by Nicolls et al\(^{[27]}\). Others histological analysis of lungs reported extensive interstitial and alveolar lung infiltration by maturing myeloid cells, endothelial cells damage, oedema, hemorrhage, and fibrinous exudates that correspond in poorly defined centrolobular nodules and ground-glass opacity with or without interlobular septal thickening.

To our knowledge only a few cases are reported describing the CT aspect in DS: Davis et al\(^{[28]}\) reported CT findings in three patients with DS. CT findings were peripheral nodules reticular and ground-glass opacity and pleural effusions. They also reported the case of a patient with DS who developed pneumothorax\(^{[29]}\).

In mild DS, lesions are prevalent in the lower lobes, while in severe DS, lesions are ubiquitary, with no difference within peripheral or central regions\(^{[6,9]}\).

In Figure 1, we present the correlation with radiological findings and white blood cells (WBC). The pathogenesis of DS suggest that this syndrome is due to a massive lung interstitial invasion by leukemic cells. The finding of a negative peak of WBC nearly contemporary to the massive lung oedema seems to confirm this theory.

Patients with PML and DS have an highly compromised immune system; therefore, it is not a rare event to find other concurrent pathologic conditions as pneumonia or fungine infections which can confound the radiological picture of DS/ATRA syndrome.

CT findings of ATRA syndrome are nonspecific (Figure 2).

All findings have differential diagnoses: leukemic infiltrates, drug toxicity, pulmonary edema, hemorrhage, can all have similar appearances.
Although the imaging features are not characteristic, in combination with the clinical picture, they may contribute to the early identification of DS and consequently to its fast resolution (Figures 3 and 4).

**CONCLUSION**

Diagnosis of DS requires a great skill for radiologists and hematologists, and cooperation and treatment is of utmost importance when DS is confirmed.

Chest X-ray still remains the first imaging step, but often, in mild cases, it is not sufficient.

In summary chest X-ray features include increased cardiothoracic ratio and vascular pedicle width, interstitial edema with peribronchial cuffing and Kerley lines.

The chest CT is useful to evaluate the lung parenchyma and also to discover other signs of severity, as pericardial and pleural effusions, and sometimes to find

---

**Figure 2 Photograph.** A: Chest X-ray shows subtle patchy ground glass opacities of the middle inferior lung fields; B: Computed tomography scans of the same patient as Figure 4 shows patchy ground glass opacities (a, b and c) with interlobar septal thickening (arrows d). References: Institute of Radiology, Department of Clinical and Biological Sciences of University of Turin, AOU S.Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Torino, Italy.

**Figure 3 Supine Chest X-ray showing bilateral, asymmetrical patchy consolidation.** Septal lines and pleural effusions are absent. Based on the only radiologic features, it would be difficult to differentiate one from acute respiratory distress syndrome or hemorrhage on these findings. References: Institute of Radiology, Department of Clinical and Biological Sciences of University of Turin, AOU S.Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Torino, Italy.
others concurrent lung infections.

Take home message: (1) Suspect DS in patient with acute APL under treatment with ATRA and/or arsenic trioxide; (2) Detect the early signs of DS to confirm the clinical diagnosis; (3) Examine the patient’s behaviour; and (4) Rapidly detect and treat the complications.

REFERENCES

1. Rego EM, De Santis GC. Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. *Medit J Hematol Infect Dis* 2011; 3: e2011048 [PMID: 2210898 DOI: 10.4084/MJHID.2011.048]

2. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. *Blood* 1999; 93: 3167-3215 [PMID: 10238781]

3. Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. *J Oncol Pract* 2012; 18: 109-114 [PMID: 21364078 DOI: 10.1177/107815521399163]

4. Sanz MA, Grimaud D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F, Sanz MA. Causes of acute promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17). *Leukemia* 2000; 14: 1197-1200 [PMID: 10914542]

5. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. *Blood* 2008; 111: 3395-3402 [PMID: 18195095]

6. Patanian E, Thompson DF. Retinoic acid syndrome: a review. *J Clin Pharm Ther* 2008; 33: 331-338 [PMID: 18613850]

7. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood* 2008; 111: 2505-2515 [PMID: 18299451 DOI: 10.1182/blood-2007-07-102798]

8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Willman CL. Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17). *Leukemia* 2000; 14: 1197-1200 [PMID: 10914542]

9. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. *Blood* 2008; 111: 3395-3402 [PMID: 18195095]

10. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. *Oncologist* 2001; 6 Suppl 2: 29-32 [PMID: 11331438]

11. Gupta V, Yi QL, Brandwein J, Lipton JH, Messner HA, Schuh AC, Wells RA, Minden MD. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. *Leukemia* 2003; 17: 339-342 [PMID: 12992332]

12. de Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zitoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Mahkoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P. Incidence, clinical features, and outcome of all-trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. *Blood* 1998; 92: 2512-2518 [PMID: 9763554]

13. de Botton S, Chevet S, Coiteux V, Dombret H, Sanz M, Miguel JS, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Fey M, Cony Mahkoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. *Leukemia* 2003; 17: 339-342 [PMID: 12992332]

14. Patanian E, Thompson DF. Retinoic acid syndrome: a review. *J Clin Pharm Ther* 2008; 33: 331-338 [PMID: 18613850]

15. Luessink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, de Witte TJ, van der Reijden BA, Jansen JH. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. *Blood* 2009; 114: 5512-5521 [PMID: 19826968 DOI: 10.1182/blood-2009-02-208434]

16. de Botton S, Chevet S, Coiteux V, Dombret H, Sanz M, Miguel JS, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Mahkoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. *Leukemia* 2003; 17: 339-342 [PMID: 12992332]

17. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. *Oncologist* 2001; 6 Suppl 2: 29-32 [PMID: 11331438]

18. Gupta V, Yi QL, Brandwein J, Lipton JH, Messner HA, Schuh AC, Wells RA, Minden MD. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. *Leukemia* 2003; 17: 339-342 [PMID: 12992332]

19. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. *Oncologist* 2001; 6 Suppl 2: 29-32 [PMID: 11331438]

20. Roche Laboratories, Inc. Vesanoid (tretinoin) package insert. Nutley, NJ, 2004. Available from: URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/204386s004lbl.pdf

21. Nasr R, Lallemant-Breitenbach V, Zhu J, Guillemin MC, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. *Clin Cancer Res* 2009; 15: 6321-6326 [DOI: 10.1158/1078-0432.CCR-09-0209]

22. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. *Best Pract Res Clin Haematol* 2003; 16: 453-461 [PMID: 12939682]

23. Luessink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukemia. *Br J Haematol* 2010; 151: 209-220 [PMID: 20735400 DOI: 10.1111/j.1365-2141.2010.08325.x]

24. Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracry-
cline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113: 775-783 [PMID: 18945964 DOI: 10.1182/blood-2008-07-166617]

21 Acute Myeloid Leukemia NCCN Clinical Practice Guidelines in Oncology (Version 2.2014) Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995; 9: 774-778 [PMID: 07769839]

22 Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolofer P. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243 [PMID: 14576047]

23 Jung JI, Choi JE, Hahn ST, Min CK, Kim CC, Park SH. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol 2002; 178: 475-480 [PMID: 11804921]

24 Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296 [PMID: 1637024]

25 Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, François C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90-95 [PMID: 10607690]

26 Nicolls MR, Terada LS, Tudor RM, Prindiville SA, Schwarz MI. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158: 1302-1305 [PMID: 9769296]

27 Davis BA, Cervi P, Amin Z, Moshi G, Shaw P, Porter J. Retinoic acid syndrome: pulmonary computed tomography (CT) findings. Leuk Lymphoma 1996; 23: 113-117 [PMID: 9021693]

P- Reviewer: Agarwal R, Sureka B S- Editor: Wen LL L- Editor: A E- Editor: Liu SQ
